article thumbnail

GLP-1s Effective as Adjunctive Therapy in Patients with T1D, Obesity | ADA 2025

Drug Topics

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were safe and effective as adjunctive therapies for patients with type 1 diabetes (T1D) and overweight or obesity, according to an abstract presented at the American Diabetes Association 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025.

article thumbnail

Meeting Preview: McKesson ideaShare 2025

Drug Topics

The Opportunities, Gaps in Diabetes Care Making Pharmacists Stand Out | ADA 2025 Brian Nowosielski ; Jon Easter, RPh July 4th 2025 Podcast Following his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter caught up with Drug Topics to discuss the pharmacists’ role in diabetes management.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position

STAT

The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options.    Now, hundreds of thousands of patients are stuck navigating uncharted waters as companies they entrusted with their health pursue strategies that may disrupt their care or present risks.

article thumbnail

Q&A: Pharmacist Highlights Challenges in Vaccine Information Navigation Amid Changing Recommendations

Drug Topics

CDC Report Finds No Connection Between Thimerosal and Autism Ashley Gallagher June 25th 2025 Article Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s. You could view them; you could view the meeting videos.

Vaccines 459
article thumbnail

CGM Usage Improves Glycemic, Psychosocial Outcomes for Type 1 Diabetes | ADA 2025

Drug Topics

link] Recent Videos Related Content Pharmacist Outreach Reduces Therapeutic Inertia in T2D | ADA 2025 Killian Meara June 23rd 2025 Article Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

article thumbnail

Smart Insulin Pen Cap System Shows Sustained Glycemic Improvement Over 12 Months | ADA 2025

Drug Topics

A smart insulin pen cap system that integrates with continuous glucose monitors (CGM) to provide alerts in real time showed sustained glycemic improvement and reduced diabetes distress through 12 months, according to data presented at the American Diabetes Association’s 85th Scientific Sessions, which were held June 20-23 in Chicago, Illinois.

article thumbnail

Deucravacitinib Shows Joint, Skin Symptom Improvements in Psoriatic Arthritis

Drug Topics

The data from POETYK PsA-1 is being presented at the European Alliance of Associations for Rheumatology Congress, being held in Barcelona, Spain, from June 11 to 14. Additionally, a significantly greater proportion of patients who received the therapy did not have radiographic progression. References 1.